JP7509745B2 - ポリヌクレオチド合成方法、キット、およびシステム - Google Patents
ポリヌクレオチド合成方法、キット、およびシステム Download PDFInfo
- Publication number
- JP7509745B2 JP7509745B2 JP2021500840A JP2021500840A JP7509745B2 JP 7509745 B2 JP7509745 B2 JP 7509745B2 JP 2021500840 A JP2021500840 A JP 2021500840A JP 2021500840 A JP2021500840 A JP 2021500840A JP 7509745 B2 JP7509745 B2 JP 7509745B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- strand
- polynucleotide
- cycle
- supporting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000040430 polynucleotide Human genes 0.000 title claims description 833
- 108091033319 polynucleotide Proteins 0.000 title claims description 833
- 239000002157 polynucleotide Substances 0.000 title claims description 832
- 238000001308 synthesis method Methods 0.000 title description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 1259
- 239000002773 nucleotide Substances 0.000 claims description 1257
- 238000000034 method Methods 0.000 claims description 352
- 230000008093 supporting effect Effects 0.000 claims description 262
- 238000003786 synthesis reaction Methods 0.000 claims description 224
- 230000015572 biosynthetic process Effects 0.000 claims description 221
- 238000010348 incorporation Methods 0.000 claims description 217
- 238000003776 cleavage reaction Methods 0.000 claims description 212
- 230000007017 scission Effects 0.000 claims description 198
- 230000000295 complement effect Effects 0.000 claims description 140
- 102000004190 Enzymes Human genes 0.000 claims description 128
- 108090000790 Enzymes Proteins 0.000 claims description 128
- 230000002441 reversible effect Effects 0.000 claims description 116
- 238000006243 chemical reaction Methods 0.000 claims description 103
- 230000009471 action Effects 0.000 claims description 43
- 102000003960 Ligases Human genes 0.000 claims description 31
- 108090000364 Ligases Proteins 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 28
- 229920002401 polyacrylamide Polymers 0.000 claims description 23
- -1 bromoacetyl groups Chemical group 0.000 claims description 20
- 108020004635 Complementary DNA Proteins 0.000 claims description 19
- 102000003832 Nucleotidyltransferases Human genes 0.000 claims description 19
- 108090000119 Nucleotidyltransferases Proteins 0.000 claims description 19
- 125000000524 functional group Chemical group 0.000 claims description 19
- 230000000717 retained effect Effects 0.000 claims description 15
- 108010082610 Deoxyribonuclease (Pyrimidine Dimer) Proteins 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 208000035657 Abasia Diseases 0.000 claims description 10
- 102000004099 Deoxyribonuclease (Pyrimidine Dimer) Human genes 0.000 claims description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- KVLNTIPUCYZQHA-UHFFFAOYSA-N n-[5-[(2-bromoacetyl)amino]pentyl]prop-2-enamide Chemical compound BrCC(=O)NCCCCCNC(=O)C=C KVLNTIPUCYZQHA-UHFFFAOYSA-N 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- 101710081048 Endonuclease III Proteins 0.000 claims description 5
- 238000005304 joining Methods 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 125000001391 thioamide group Chemical group 0.000 claims description 5
- 108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 claims description 4
- 102100035619 DNA-(apurinic or apyrimidinic site) lyase Human genes 0.000 claims description 3
- 108010000577 DNA-Formamidopyrimidine Glycosylase Proteins 0.000 claims description 3
- 108090000856 Lyases Proteins 0.000 claims description 3
- 102000004317 Lyases Human genes 0.000 claims description 3
- 102000018054 AP endonuclease 1 Human genes 0.000 claims 1
- 108050007143 AP endonuclease 1 Proteins 0.000 claims 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 96
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 96
- 108091034117 Oligonucleotide Proteins 0.000 description 74
- 108020004414 DNA Proteins 0.000 description 64
- 239000000047 product Substances 0.000 description 58
- 238000010511 deprotection reaction Methods 0.000 description 48
- 125000005647 linker group Chemical group 0.000 description 47
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 45
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 42
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 42
- 239000000499 gel Substances 0.000 description 42
- 239000003153 chemical reaction reagent Substances 0.000 description 41
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 34
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 26
- SGPUHRSBWMQRAN-UHFFFAOYSA-N 2-[bis(1-carboxyethyl)phosphanyl]propanoic acid Chemical compound OC(=O)C(C)P(C(C)C(O)=O)C(C)C(O)=O SGPUHRSBWMQRAN-UHFFFAOYSA-N 0.000 description 25
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 24
- 239000012634 fragment Substances 0.000 description 24
- 102000004357 Transferases Human genes 0.000 description 23
- 108090000992 Transferases Proteins 0.000 description 23
- 229940104302 cytosine Drugs 0.000 description 21
- 150000007523 nucleic acids Chemical group 0.000 description 20
- 230000002194 synthesizing effect Effects 0.000 description 20
- 229940113082 thymine Drugs 0.000 description 20
- 230000000903 blocking effect Effects 0.000 description 19
- 238000010586 diagram Methods 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 238000010189 synthetic method Methods 0.000 description 17
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- 230000000670 limiting effect Effects 0.000 description 15
- 239000002777 nucleoside Substances 0.000 description 15
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 102000012410 DNA Ligases Human genes 0.000 description 14
- 108010061982 DNA Ligases Proteins 0.000 description 14
- 125000006850 spacer group Chemical group 0.000 description 14
- 239000001226 triphosphate Substances 0.000 description 13
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 12
- 229960005305 adenosine Drugs 0.000 description 12
- 108010017826 DNA Polymerase I Proteins 0.000 description 11
- 102000004594 DNA Polymerase I Human genes 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 238000009739 binding Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 239000005549 deoxyribonucleoside Substances 0.000 description 10
- 230000002255 enzymatic effect Effects 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002342 ribonucleoside Substances 0.000 description 10
- 102100031780 Endonuclease Human genes 0.000 description 9
- 229930010555 Inosine Natural products 0.000 description 9
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 229960003786 inosine Drugs 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 8
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 8
- 102100037696 Endonuclease V Human genes 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 description 8
- 230000006820 DNA synthesis Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 235000011178 triphosphate Nutrition 0.000 description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
- 241000205101 Sulfolobus Species 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000006819 RNA synthesis Effects 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- NZJKEQFPRPAEPO-UHFFFAOYSA-N 1h-benzimidazol-4-amine Chemical compound NC1=CC=CC2=C1N=CN2 NZJKEQFPRPAEPO-UHFFFAOYSA-N 0.000 description 3
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 3
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 3
- 108010034927 3-methyladenine-DNA glycosylase Proteins 0.000 description 3
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 3
- NEJMFSBXFBFELK-UHFFFAOYSA-N 4-nitro-1h-benzimidazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1N=CN2 NEJMFSBXFBFELK-UHFFFAOYSA-N 0.000 description 3
- LAVZKLJDKGRZJG-UHFFFAOYSA-N 4-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C=CN2 LAVZKLJDKGRZJG-UHFFFAOYSA-N 0.000 description 3
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 3
- WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 3
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 3
- PSWCIARYGITEOY-UHFFFAOYSA-N 6-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2C=CNC2=C1 PSWCIARYGITEOY-UHFFFAOYSA-N 0.000 description 3
- 108010001132 DNA Polymerase beta Proteins 0.000 description 3
- 102000001996 DNA Polymerase beta Human genes 0.000 description 3
- 102100029765 DNA polymerase lambda Human genes 0.000 description 3
- 101710177421 DNA polymerase lambda Proteins 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 241000205188 Thermococcus Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 102100039128 DNA-3-methyladenine glycosylase Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102100026406 G/T mismatch-specific thymine DNA glycosylase Human genes 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010035344 Thymine DNA Glycosylase Proteins 0.000 description 2
- 108010001244 Tli polymerase Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000002431 aminoalkoxy group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000002508 contact lithography Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 125000006502 nitrobenzyl group Chemical group 0.000 description 2
- 229920002842 oligophosphate Polymers 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- MYAJTCUQMQREFZ-UHFFFAOYSA-K tppts Chemical compound [Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC=CC(P(C=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=C(C=CC=2)S([O-])(=O)=O)=C1 MYAJTCUQMQREFZ-UHFFFAOYSA-K 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical group NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- GUXJXWKCUUWCLX-UHFFFAOYSA-N 2-methyl-2-oxazoline Chemical compound CC1=NCCO1 GUXJXWKCUUWCLX-UHFFFAOYSA-N 0.000 description 1
- HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 1
- BCAIDFOKQCVACE-UHFFFAOYSA-N 3-[dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azaniumyl]propane-1-sulfonate Chemical compound CC(=C)C(=O)OCC[N+](C)(C)CCCS([O-])(=O)=O BCAIDFOKQCVACE-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108010057896 5-methylcytosine-DNA glycosylase Proteins 0.000 description 1
- DPRSKJHWKNHBOW-UHFFFAOYSA-N 7-Deazainosine Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2C=C1 DPRSKJHWKNHBOW-UHFFFAOYSA-N 0.000 description 1
- LSMBOEFDMAIXTM-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-imidazo[4,5-d]triazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NN=NC(O)=C2N=C1 LSMBOEFDMAIXTM-UUOKFMHZSA-N 0.000 description 1
- DPRSKJHWKNHBOW-KCGFPETGSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2C=C1 DPRSKJHWKNHBOW-KCGFPETGSA-N 0.000 description 1
- IHLOTZVBEUFDMD-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,2-dioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 IHLOTZVBEUFDMD-UUOKFMHZSA-N 0.000 description 1
- QFFLRMDXYQOYKO-KVQBGUIXSA-N 7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-imidazo[4,5-d]triazin-4-one Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NN=NC(O)=C2N=C1 QFFLRMDXYQOYKO-KVQBGUIXSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000664956 Homo sapiens Single-strand selective monofunctional uracil DNA glycosylase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical class OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229920000550 glycopolymer Polymers 0.000 description 1
- 102000055291 human SMUG1 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002796 nucleotidyl group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007651 thermal printing Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811811.7A GB201811811D0 (en) | 2018-07-19 | 2018-07-19 | Method |
| GB1811811.7 | 2018-07-19 | ||
| PCT/GB2019/052036 WO2020016605A1 (en) | 2018-07-19 | 2019-07-19 | Polynucleotide synthesis method, kit and system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529548A JP2021529548A (ja) | 2021-11-04 |
| JP2021529548A5 JP2021529548A5 (https=) | 2022-06-30 |
| JP7509745B2 true JP7509745B2 (ja) | 2024-07-02 |
Family
ID=63364456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500840A Active JP7509745B2 (ja) | 2018-07-19 | 2019-07-19 | ポリヌクレオチド合成方法、キット、およびシステム |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12037636B2 (https=) |
| EP (1) | EP3823755A1 (https=) |
| JP (1) | JP7509745B2 (https=) |
| CN (1) | CN112423885B (https=) |
| AU (1) | AU2019307836B2 (https=) |
| CA (1) | CA3104698A1 (https=) |
| GB (1) | GB201811811D0 (https=) |
| WO (1) | WO2020016605A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2559117B (en) | 2017-01-19 | 2019-11-27 | Oxford Nanopore Tech Ltd | Double stranded polynucleotide synthesis method, kit and system |
| GB2574197B (en) * | 2018-05-23 | 2022-01-05 | Oxford Nanopore Tech Ltd | Double stranded polynucleotide synthesis method and system. |
| GB201811810D0 (en) * | 2018-07-19 | 2018-09-05 | Oxford Nanopore Tech Ltd | Method |
| GB201811813D0 (en) * | 2018-07-19 | 2018-09-05 | Oxford Nanopore Tech Ltd | Method |
| GB201811811D0 (en) | 2018-07-19 | 2018-09-05 | Oxford Nanopore Tech Ltd | Method |
| US20230117083A1 (en) * | 2020-01-22 | 2023-04-20 | Nuclera Nucleics Ltd. | Methods of nucleic acid synthesis |
| GB202013102D0 (en) * | 2020-08-21 | 2020-10-07 | Nuclera Nucleics Ltd | Methods of nucleic acid synthesis |
| GB202309649D0 (en) * | 2023-06-27 | 2023-08-09 | Oxford Nanopore Tech Plc | Method |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001088173A2 (en) | 2000-05-16 | 2001-11-22 | Hercules Incorporated | Methods for the enzymatic assembly of polynucleotides and identification of polynucleotides having desired characteristics |
| JP2007532120A (ja) | 2004-04-14 | 2007-11-15 | オリソン、ヘノミクス、ソシエダッド、アノニマ | 核酸分子のサブセットを選択的に検出するための方法 |
| US20130085073A1 (en) | 2011-09-29 | 2013-04-04 | Illumina Cambridge Limited | Continuous extension and deblocking in reactions for nuclleic acids synthesis and sequencing |
| JP2014504153A (ja) | 2010-11-12 | 2014-02-20 | ジェン９・インコーポレイテッド | 核酸合成のための方法およびデバイス |
| JP2016515391A (ja) | 2013-10-15 | 2016-05-30 | モレキュラー アセンブリー， エルエルシー | 核酸を合成するための方法および装置 |
| WO2017223517A1 (en) | 2016-06-24 | 2017-12-28 | The Regents Of The University Of California | Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates |
| JP2020506687A (ja) | 2017-01-19 | 2020-03-05 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチド分子を合成するための方法および試薬 |
| JP2021524246A (ja) | 2018-05-23 | 2021-09-13 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチドの合成法、システム、およびキット |
| JP2021529549A (ja) | 2018-07-19 | 2021-11-04 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチドの合成法、キット、およびシステム |
| JP2021529551A (ja) | 2018-07-19 | 2021-11-04 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチドの合成法、キット、およびシステム |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5438131A (en) | 1992-09-16 | 1995-08-01 | Bergstrom; Donald E. | 3-nitropyrrole nucleoside |
| US6190865B1 (en) * | 1995-09-27 | 2001-02-20 | Epicentre Technologies Corporation | Method for characterizing nucleic acid molecules |
| US8137906B2 (en) | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
| DE19925862A1 (de) | 1999-06-07 | 2000-12-14 | Diavir Gmbh | Verfahren zur Synthese von DNA-Fragmenten |
| EP1314783B1 (de) | 2001-11-22 | 2008-11-19 | Sloning BioTechnology GmbH | Nukleinsäure-Linker und deren Verwendung in der Gensynthese |
| JP4663988B2 (ja) | 2002-04-12 | 2011-04-06 | ニュー・イングランド・バイオラブズ・インコーポレイティッド | Ｄｎａ操作のための方法および組成物 |
| DE10223057A1 (de) | 2002-05-24 | 2003-12-11 | Basf Ag | Verfahren zur Erzeugung von Polynukleotidmolekülen |
| DK1670914T3 (da) | 2003-10-02 | 2008-05-13 | Basf Se | Fremgangsmåde til sekvensmætnings-mutangenese (SeSaM) |
| US20090006002A1 (en) | 2007-04-13 | 2009-01-01 | Sequenom, Inc. | Comparative sequence analysis processes and systems |
| US8716190B2 (en) | 2007-09-14 | 2014-05-06 | Affymetrix, Inc. | Amplification and analysis of selected targets on solid supports |
| WO2010025310A2 (en) | 2008-08-27 | 2010-03-04 | Westend Asset Clearinghouse Company, Llc | Methods and devices for high fidelity polynucleotide synthesis |
| US9187777B2 (en) | 2010-05-28 | 2015-11-17 | Gen9, Inc. | Methods and devices for in situ nucleic acid synthesis |
| US8653832B2 (en) | 2010-07-06 | 2014-02-18 | Sharp Kabushiki Kaisha | Array element circuit and active matrix device |
| US8828336B2 (en) | 2011-02-02 | 2014-09-09 | Sharp Kabushiki Kaisha | Active matrix device |
| EP2807292B1 (en) | 2012-01-26 | 2019-05-22 | Tecan Genomics, Inc. | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation |
| JP6375301B2 (ja) | 2012-10-26 | 2018-08-15 | オックスフォード ナノポール テクノロジーズ リミテッド | 液滴界面 |
| US9492824B2 (en) | 2013-01-16 | 2016-11-15 | Sharp Kabushiki Kaisha | Efficient dilution method, including washing method for immunoassay |
| US9169573B2 (en) | 2013-01-23 | 2015-10-27 | Sharp Kabushiki Kaisha | AM-EWOD device and method of driving with variable voltage AC driving |
| US9279149B2 (en) | 2013-04-02 | 2016-03-08 | Molecular Assemblies, Inc. | Methods and apparatus for synthesizing nucleic acids |
| US9771613B2 (en) | 2013-04-02 | 2017-09-26 | Molecular Assemblies, Inc. | Methods and apparatus for synthesizing nucleic acid |
| US10683536B2 (en) | 2013-04-02 | 2020-06-16 | Molecular Assemblies, Inc. | Reusable initiators for synthesizing nucleic acids |
| US8808989B1 (en) | 2013-04-02 | 2014-08-19 | Molecular Assemblies, Inc. | Methods and apparatus for synthesizing nucleic acids |
| CN117947149A (zh) | 2013-10-18 | 2024-04-30 | 牛津纳米孔科技公开有限公司 | 经修饰的酶 |
| CN111534504B (zh) | 2014-01-22 | 2024-06-21 | 牛津纳米孔科技公开有限公司 | 将一个或多个多核苷酸结合蛋白连接到靶多核苷酸的方法 |
| FR3020071B1 (fr) | 2014-04-17 | 2017-12-22 | Dna Script | Procede de synthese d'acides nucleiques, notamment d'acides nucleiques de grande longueur, utilisation du procede et kit pour la mise en œuvre du procede |
| US20170218416A1 (en) | 2014-05-16 | 2017-08-03 | The Regents Of The University Of California | Compositions and methods for single-molecule construction of dna |
| FR3025201B1 (fr) | 2014-09-02 | 2018-10-12 | Dna Script | Nucleotides modifies pour la synthese d'acides nucleiques, un kit renfermant de tels nucleotides et leur utilisation pour la production de genes ou sequences d'acides nucleiques synthetiques |
| EP3699283A1 (en) | 2014-10-20 | 2020-08-26 | Molecular Assemblies Inc. | Modified template-independent enzymes for polydeoxynucleotide systhesis |
| GB201502152D0 (en) | 2015-02-10 | 2015-03-25 | Nuclera Nucleics Ltd | Novel use |
| GB201503534D0 (en) | 2015-03-03 | 2015-04-15 | Nuclera Nucleics Ltd | Novel method |
| GB201512372D0 (en) | 2015-07-15 | 2015-08-19 | Nuclera Nucleics Ltd | Novel method |
| EP3737755B1 (en) | 2018-01-12 | 2024-08-28 | Camena Bioscience Limited | Method for template-free geometric enzymatic nucleic acid synthesis |
| GB201801768D0 (en) | 2018-02-02 | 2018-03-21 | Oxford Nanopore Tech Ltd | Synthesis method |
| GB201811811D0 (en) | 2018-07-19 | 2018-09-05 | Oxford Nanopore Tech Ltd | Method |
| GB201913039D0 (en) | 2019-09-10 | 2019-10-23 | Oxford Nanopore Tech Ltd | Polynicleotide synthesis method kit and system |
-
2018
- 2018-07-19 GB GBGB1811811.7A patent/GB201811811D0/en not_active Ceased
-
2019
- 2019-07-19 WO PCT/GB2019/052036 patent/WO2020016605A1/en not_active Ceased
- 2019-07-19 CA CA3104698A patent/CA3104698A1/en active Pending
- 2019-07-19 AU AU2019307836A patent/AU2019307836B2/en active Active
- 2019-07-19 US US17/260,615 patent/US12037636B2/en active Active
- 2019-07-19 JP JP2021500840A patent/JP7509745B2/ja active Active
- 2019-07-19 CN CN201980048339.XA patent/CN112423885B/zh active Active
- 2019-07-19 EP EP19748893.5A patent/EP3823755A1/en active Pending
-
2024
- 2024-06-05 US US18/734,734 patent/US20250084468A1/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001088173A2 (en) | 2000-05-16 | 2001-11-22 | Hercules Incorporated | Methods for the enzymatic assembly of polynucleotides and identification of polynucleotides having desired characteristics |
| JP2007532120A (ja) | 2004-04-14 | 2007-11-15 | オリソン、ヘノミクス、ソシエダッド、アノニマ | 核酸分子のサブセットを選択的に検出するための方法 |
| JP2014504153A (ja) | 2010-11-12 | 2014-02-20 | ジェン９・インコーポレイテッド | 核酸合成のための方法およびデバイス |
| US20130085073A1 (en) | 2011-09-29 | 2013-04-04 | Illumina Cambridge Limited | Continuous extension and deblocking in reactions for nuclleic acids synthesis and sequencing |
| JP2016515391A (ja) | 2013-10-15 | 2016-05-30 | モレキュラー アセンブリー， エルエルシー | 核酸を合成するための方法および装置 |
| WO2017223517A1 (en) | 2016-06-24 | 2017-12-28 | The Regents Of The University Of California | Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates |
| JP2020506687A (ja) | 2017-01-19 | 2020-03-05 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチド分子を合成するための方法および試薬 |
| JP2021524246A (ja) | 2018-05-23 | 2021-09-13 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチドの合成法、システム、およびキット |
| JP2021529549A (ja) | 2018-07-19 | 2021-11-04 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチドの合成法、キット、およびシステム |
| JP2021529551A (ja) | 2018-07-19 | 2021-11-04 | オックスフォード ナノポール テクノロジーズ リミテッド | ポリヌクレオチドの合成法、キット、およびシステム |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250084468A1 (en) | 2025-03-13 |
| WO2020016605A1 (en) | 2020-01-23 |
| GB201811811D0 (en) | 2018-09-05 |
| US12037636B2 (en) | 2024-07-16 |
| EP3823755A1 (en) | 2021-05-26 |
| CA3104698A1 (en) | 2020-01-23 |
| CN112423885A (zh) | 2021-02-26 |
| AU2019307836A1 (en) | 2021-01-07 |
| US20220213537A1 (en) | 2022-07-07 |
| CN112423885B (zh) | 2023-07-04 |
| AU2019307836B2 (en) | 2024-04-04 |
| JP2021529548A (ja) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7393351B2 (ja) | ポリヌクレオチドの合成法、システム、およびキット | |
| KR102618717B1 (ko) | 폴리뉴클레오티드 분자의 합성을 위한 방법 및 시약 | |
| JP7509745B2 (ja) | ポリヌクレオチド合成方法、キット、およびシステム | |
| JP7518812B2 (ja) | ポリヌクレオチドの合成法、キット、およびシステム | |
| JP7393412B2 (ja) | ポリヌクレオチドの合成法、キット、およびシステム | |
| US20220396818A1 (en) | Polynucleotide synthesis method, kit and system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220622 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220622 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231019 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240321 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240618 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240620 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7509745 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |